Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use may reduce alcohol consumption and improve outcomes in some ...

The impact of GLP-1 RAs on alcohol use is explored, showing potential benefits in reducing intake and cravings, but with ...

Wegovy is a once-weekly injection approved by the U.S. Food and Drug Administration (FDA) to treat obesity in people 12 and ...

A recent study found that glucagon-like peptide-1 receptor (GLP-1) agonists like semaglutide and liraglutide are effective in ...

In a subgroup analysis, there was a positive effect in people with obesity, with significant reductions in brain reward center cue reactivity on functional magnetic resonance imaging. (HealthDay ...

However, authors caution there is little high-quality evidence. (HealthDay News) — Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use may reduce alcohol consumption and improve outcomes in ...

And more than half of Chinese adults are now overweight or obese, according to a 2021 study. Now that glucagon-like peptide-1 ...

Study: Association between glucagon-like peptide-1 receptor agonists use and change in alcohol consumption: a systematic review. Image Credit: Kmpzzz/Shutterstock.com In a recent study published ...

Unlike scores of people who scrambled for the blockbuster drugs Ozempic and Wegovy to lose weight in recent years, Danielle ...

A collection of studies presented at a recent American Heart Association (AHA) conference has confirmed the heart health benefits provided by the new anti-obesity drugs, semaglutide and tirzepatide, ...

Certain whole foods like oats, avocados, and lentils can mimic the effects of Ozempic, boosting the release of your GLP-1.

Popular weight loss drugs have been linked to gastrointestinal, mental health, and vision problems, but the benefits appear ...